Scholar Rock FY2027 EPS Forecast Raised by HC Wainwright

Scholar Rock Holding Corporation (NASDAQ:SRRK) – Equities research analysts at HC Wainwright boosted their FY2027 earnings estimates for Scholar Rock in a research note issued to investors on Monday, January 26th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($2.28) per share for the year, up from their prior forecast of ($2.39). HC Wainwright currently has a “Buy” rating and a $58.00 target price on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Scholar Rock’s FY2028 earnings at ($0.92) EPS and FY2029 earnings at $0.17 EPS.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.02). During the same quarter last year, the firm posted ($0.66) earnings per share.

Other research analysts have also recently issued reports about the stock. Bank of America began coverage on shares of Scholar Rock in a research report on Thursday, October 9th. They set a “buy” rating and a $53.00 target price on the stock. Citigroup began coverage on shares of Scholar Rock in a research report on Friday, January 9th. They issued a “buy” rating and a $55.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a research report on Thursday, January 22nd. Wolfe Research began coverage on Scholar Rock in a report on Tuesday, November 18th. They issued an “outperform” rating and a $42.00 price objective for the company. Finally, JPMorgan Chase & Co. upped their target price on Scholar Rock from $46.00 to $47.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. Four investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Scholar Rock currently has a consensus rating of “Buy” and a consensus price target of $51.14.

Scholar Rock Price Performance

SRRK stock opened at $43.99 on Wednesday. The company has a market cap of $4.49 billion, a PE ratio of -13.97 and a beta of 0.63. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41. Scholar Rock has a 12-month low of $22.71 and a 12-month high of $48.28. The stock has a 50-day moving average price of $43.98 and a two-hundred day moving average price of $37.42.

Hedge Funds Weigh In On Scholar Rock

Institutional investors have recently added to or reduced their stakes in the stock. Three Seasons Wealth LLC increased its holdings in shares of Scholar Rock by 2.1% during the fourth quarter. Three Seasons Wealth LLC now owns 10,968 shares of the company’s stock worth $483,000 after buying an additional 222 shares in the last quarter. Principal Financial Group Inc. raised its position in Scholar Rock by 7.9% in the third quarter. Principal Financial Group Inc. now owns 6,214 shares of the company’s stock valued at $231,000 after purchasing an additional 456 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Scholar Rock by 15.8% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,668 shares of the company’s stock valued at $130,000 after purchasing an additional 500 shares during the last quarter. California State Teachers Retirement System boosted its stake in shares of Scholar Rock by 0.9% during the second quarter. California State Teachers Retirement System now owns 62,372 shares of the company’s stock valued at $2,209,000 after purchasing an additional 577 shares in the last quarter. Finally, Tema Etfs LLC grew its holdings in shares of Scholar Rock by 6.6% during the fourth quarter. Tema Etfs LLC now owns 9,899 shares of the company’s stock worth $436,000 after purchasing an additional 616 shares during the last quarter. 91.08% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, General Counsel Junlin Ho sold 8,016 shares of the business’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $44.48, for a total value of $356,551.68. Following the completion of the transaction, the general counsel owned 214,553 shares of the company’s stock, valued at $9,543,317.44. The trade was a 3.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Caryn Parlavecchio sold 6,600 shares of Scholar Rock stock in a transaction on Friday, January 16th. The shares were sold at an average price of $44.48, for a total value of $293,568.00. Following the completion of the transaction, the insider owned 148,864 shares in the company, valued at approximately $6,621,470.72. The trade was a 4.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 305,687 shares of company stock valued at $13,540,573 in the last quarter. 13.30% of the stock is currently owned by corporate insiders.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).